Show simple item record

dc.contributor.authorDeming, Meagan
dc.contributor.authorKottilil, Shyamasundaran
dc.date.accessioned2020-03-11T17:22:22Z
dc.date.available2020-03-11T17:22:22Z
dc.date.issued2020
dc.identifier.urihttp://hdl.handle.net/10713/12201
dc.descriptionPoster presented at the annual Conference on Retroviruses and Opportunistic Infection (CROI) held virtually from March 8-11, 2020.en_US
dc.description.abstractBackground: Hepatitis B virus (HBV) infections remain a global health issue with complications including liver cirrhosis and hepatocellular carcinoma. Individuals co-infected with Human Immunodeficiency Virus (HIV) and HBV have increased liver-related morbidity and mortality compared to those with HBV mono-infection. Vaccination is a potent intervention to prevent HBV infection, but certain critical populations including people living with HIV are less likely to achieve seroprotection after vaccination. Seroprotection (antibody to hepatitis B surface antigen [HBsAb] titer ≥10 IU/mL) was historically poor, with trial rates ranging from 34 to 88% and improving with immunologic reconstitution and viral suppression. We hypothesized that the seroprotection rates (SPR) in a clinic population of Veterans would reflect the improving immunologic status of the cohort.en_US
dc.language.isoen_USen_US
dc.subjectseroprotectionen_US
dc.subject.meshCoinfection--immunologyen_US
dc.subject.meshHepatitis B Vaccinesen_US
dc.subject.meshHIV Infectionen_US
dc.titleA Clinical Care Cascade for Hepatitis B Virus Vaccination in a Current Era HIV Clinicen_US
dc.typePoster/Presentationen_US
dc.identifier.ispublishedNoen_US
refterms.dateFOA2020-03-11T17:22:23Z


Files in this item

Thumbnail
Name:
UMMC_Deming_2020.pdf
Size:
357.0Kb
Format:
PDF

This item appears in the following Collection(s)

Show simple item record